92 DEPIGMENTATION Placebo ■ ViaDerm TXA ■
Blemishes Reduced
Light Dark Spots
Less Dull Skin Complexion Even Skin 60 0 10 20 30 40 50 60 70
taken on the normal skin zone (on cheekbones). An increase in the gloss rate indicates an increase in skin brightening and radiance.10,11
Skin homogeneity Skin homogeneity (ΔEab*) was conducted with a Minolta CM-700-D spectrophotometer and determines the changes in the skin tone, color hue and luminosity. Measurement was performed on the dark spot and the normal skin background near the spot, and calculates the
DAY 0
Figure 6: Percentage of satisfied subjects after 28 days of treatment with ViaDerm TXA and placebo (*p<0.05 versus baseline) ΔEab* = (Δa*2
contrast between the two zones. A decrease in this parameter indicates
reduction in the contrast between pigmented and normal skin, creating a more homogeneous, uniform and an even skin tone. Skin homogeneity is calculated according to the following formula, where a* is chrominance parameter from green to red spectrum, b* is chrominance parameter from blue to yellow, and L* is luminosity ranging from black to white spectrum.8,9,12
DAY 28 + Δb*2 80 + ΔL*2 )1/2 Δ(ΔEab*) = [ΔEab* spot] - [ΔEab* normal skin]
Red spots The number of red spots (facial vascular lesions), such as acne scars, acne lesions, post acne inflammation, erythema, rosacea and spider veins (telangiectasis), was measured using the VISIA CAS® image analysis technique. Red spots (facial vascular lesions) were
identified by the VISIA CAS cross-polarized RBX image analysis system, which measures the hemoglobin component in the skin. A decrease in the number of the red spots indicates a more even and homogenous skin appearance and a less red complexion.13,14
In vivo clinical efficacy study results Dark spot pigmentation degree The in vivo clinical efficacy study results demonstrate that after 28 days of use, tranexamic acid significantly increased the luminosity of dark spot pigmentation degree (measured by ITA°) by 30% compared to baseline, and by 18% compared to placebo, thus imparting lighter, less pigmented spots and a more even skin tone. Results are significantly better compared to baseline and placebo. The percentage change in the dark spot pigmentation degree (ITA°) after 28 days of application with tranexamic acid and placebo compared to baseline is illustrated in Figure 2.
Skin radiance The percentage change in skin radiance (measured by skin gloss rate) after 28 days of use with tranexamic acid and placebo compared to baseline is illustrated in Figure 3. Results confirm that tranexamic acid
Figure 7: Digital images of a subject (age 62) showing at baseline (Day 0) dark spots/ hyperpigmentation, uneven skin tone, lack of radiance and numerous red areas on the face. After 28 days of use with ViaDerm TXA, skin shows visibly less spots, a more even skin tone, enhanced skin radiance and reduced red areas compared to baseline and placebo skin sites
PERSONAL CARE March 2024
significantly increased skin gloss rate by 18% compared to baseline, and by 16% compared to placebo, creating a more radiant, brighter and luminous skin complexion. This highly
www.personalcaremagazine.com 90 Spots & 40 * 47 67
60
* * *
80
80
80
ViaDDerm TXA
PLACEBO
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
